SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Clinical trial NCT05293912 · TERMINATED
Trial details
- NCT number
- NCT05293912
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-03
- Primary completion
- 2023-06-30
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.